| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
In HeLa/GFP-Parkin cells, T0467 (2.5–20 μM; 3 hours) stimulates GFP-Parkin's mitochondrial translocation over 12 μM[1]. About 21% of HeLa/GFP-Parkin cells exhibit GTP-Parkin translocation to the mitochondria after being exposed to 20 μM T0467 for three hours[1]. In Drosophila, T0467 does not exhibit overt toxicity at concentrations lower than 50 μM. All of the cpds that were investigated lessened the ATP production as well as the defects in mitochondrial morphology and larval locomotion caused by PINK1 inactivation. The mitochondrial Ca2+ response in the muscles of Drosophila larvae was enhanced by T0467 and KTP[1].
|
|---|---|
| References |
| Molecular Formula |
C24H26F3N5
|
|---|---|
| Molecular Weight |
441.49
|
| Exact Mass |
441.214
|
| CAS # |
859518-94-8
|
| PubChem CID |
58603496
|
| Appearance |
Off-white to light brown solid powder
|
| LogP |
4.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
32
|
| Complexity |
560
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
N1CCN(CC2C=C(C(=CC=2)F)C2=NC(NCCC3=CC(F)=CC(=C3)F)=NC=C2)[C@@H](C)C1
|
| InChi Key |
GNYKYGZGDGZPOK-INIZCTEOSA-N
|
| InChi Code |
InChI=1S/C24H26F3N5/c1-16-14-28-8-9-32(16)15-18-2-3-22(27)21(12-18)23-5-7-30-24(31-23)29-6-4-17-10-19(25)13-20(26)11-17/h2-3,5,7,10-13,16,28H,4,6,8-9,14-15H2,1H3,(H,29,30,31)/t16-/m0/s1
|
| Chemical Name |
N-[2-(3,5-difluorophenyl)ethyl]-4-[2-fluoro-5-[[(2S)-2-methylpiperazin-1-yl]methyl]phenyl]pyrimidin-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 33.33 mg/mL (75.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2651 mL | 11.3253 mL | 22.6506 mL | |
| 5 mM | 0.4530 mL | 2.2651 mL | 4.5301 mL | |
| 10 mM | 0.2265 mL | 1.1325 mL | 2.2651 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
